Estrogen regulated gene expression in response to neoadjuvant endocrine therapy of breast cancers: Tamoxifen agonist effects dominate in the presence of an aromatase inhibitor

Breast Cancer Research and Treatment

Volumn 112, Issue 3, 2008, Pages 489-501

  Harvell, Djuana M E ^a   Richer, Jennifer K ^a   Singh, Meenakshi ^a   Spoelstra, Nicole ^a   Finlayson, Christina ^a   Borges, Virginia F ^a   Elias, Anthony D ^a   Horwitz, Kathryn B ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Antiestrogens; Aromatase inhibitors; Breast cancer; Estrogen receptors; Microarray expression profiling; Neoadjuvant endocrine therapy

Indexed keywords

ANDROGEN RECEPTOR; ANTIESTROGEN; AROMATASE INHIBITOR; ESTROGEN; ESTROGEN RECEPTOR; EXEMESTANE; PLACEBO; PROGESTERONE RECEPTOR; RNA; TAMOXIFEN;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST BIOPSY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; FEMALE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MONOTHERAPY; MOUSE; NONHUMAN; NUDE MOUSE; OVARIECTOMY; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR XENOGRAFT;

ANDROSTADIENES; ANIMALS; ANTINEOPLASTIC AGENTS; AROMATASE INHIBITORS; BREAST NEOPLASMS; ENZYME INHIBITORS; ESTROGENS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, NUDE; RECEPTORS, ESTROGEN; TAMOXIFEN;

EID: 56549121407     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-008-9923-6     Document Type: Article

References (54)

1. D Chalbos F Vignon I Keydar H Rochefort 1982 Estrogens stimulate cell proliferation and induce secretory proteins in a human breast cancer cell line (T47D) J Clin Endocrinol Metab 55 276 283
2. J Russo IH Russo 2006 The role of estrogen in the initiation of breast cancer J Steroid Biochem Mol Biol 102 89 96
3. G Beatson 1896 On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases Lancet 147 101 107
4. IE Smith M Dowsett 2003 Aromatase inhibitors in breast cancer N Engl J Med 348 2431 2442
5. CK Osborne 1998 Tamoxifen in the treatment of breast cancer N Engl J Med 339 1609 1618
6. LL Shek W Godolphin 1989 Survival with breast cancer: the importance of estrogen receptor quantity Eur J Cancer Clin Oncol 25 243 250
7. N Normanno M Di Maio E De Maio 2005 Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer Endocr Relat Cancer 12 721 747
8. CK Osborne H Zhao SA Fuqua 2000 Selective estrogen receptor modulators: structure, function, and clinical use J Clin Oncol 18 3172 3186
9. B Fisher JP Costantino DL Wickerham 2005 Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study J Natl Cancer Inst 97 1652 1662
10. J Frasor F Stossi JM Danes 2004 Selective estrogen receptor modulators: discrimination of agonistic versus antagonistic activities by gene expression profiling in breast cancer cells Cancer Res 64 1522 1533
11. KB Horwitz Y Koseki WL McGuire 1978 Estrogen control of progesterone receptor in human breast cancer: role of estradiol and antiestrogen Endocrinology 103 1742 1751
12. RL Sutherland RE Hall IW Taylor 1983 Cell proliferation kinetics of MCF-7 human mammary carcinoma cells in culture and effects of tamoxifen on exponentially growing and plateau-phase cells Cancer Res 43 3998 4006
13. A Thiantanawat BJ Long AM Brodie 2003 Signaling pathways of apoptosis activated by aromatase inhibitors and antiestrogens Cancer Res 63 8037 8050
14. NR Bianco G Perry MA Smith 2003 Functional implications of antiestrogen induction of quinone reductase: inhibition of estrogen-induced deoxyribonucleic acid damage Mol Endocrinol 17 1344 1355
15. D Jelovac L Macedo V Handratta 2004 Effects of exemestane and tamoxifen in a postmenopausal breast cancer model Clin Cancer Res 10 7375 7381
16. M Baum AU Budzar J Cuzick 2002 Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial Lancet 359 2131 2139
17. IE Smith M Dowsett SR Ebbs 2005 Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial J Clin Oncol 23 5108 5116
18. Harvell DM, Spoelstra NS, Singh M et al (2007) Molecular signatures of response and intrinsic resistance to neoadjuvant endocrine therapy for breast cancer. Breast Cancer Res Treat. doi: 10.1007/s10549-008-9897-4
19. DM Harvell JK Richer DC Allred 2006 Estradiol regulates different genes in human breast tumor xenografts compared with the identical cells in culture Endocrinology 147 700 713
20. J Frasor JM Danes B Komm 2003 Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype Endocrinology 144 4562 4574
21. CJ Creighton KE Cordero JM Larios 2006 Genes regulated by estrogen in breast tumor cells in vitro are similarly regulated in vivo in tumor xenografts and human breast tumors Genome Biol 7 R28
22. Y Katoh M Katoh 2006 Canonical WNT signaling pathway and human AREG Int J Mol Med 17 1163 1166
23. M Jonsson J Dejmek PO Bendahl 2002 Loss of Wnt-5a protein is associated with early relapse in invasive ductal breast carcinomas Cancer Res 62 409 416
24. DS Salomon N Normanno F Ciardiello 1995 The role of amphiregulin in breast cancer Breast Cancer Res Treat 33 103 114
25. J Frasor EC Chang B Komm 2006 Gene expression preferentially regulated by tamoxifen in breast cancer cells and correlations with clinical outcome Cancer Res 66 7334 7340
26. RC Chambers P Leoni N Kaminski 2003 Global expression profiling of fibroblast responses to transforming growth factor-beta1 reveals the induction of inhibitor of differentiation-1 and provides evidence of smooth muscle cell phenotypic switching Am J Pathol 162 533 546
27. TE Morgan NJ Laping I Rozovsky 1995 Clusterin expression by astrocytes is influenced by transforming growth factor beta 1 and heterotypic cell interactions J Neuroimmunol 58 101 110
28. MA Alaoui-Jamali DJ Song N Benlimame 2003 Regulation of multiple tumor microenvironment markers by overexpression of single or paired combinations of ErbB receptors Cancer Res 63 3764 3774
29. MD Landis DD Seachrist ME Montanez-Wiscovich 2005 Gene expression profiling of cancer progression reveals intrinsic regulation of transforming growth factor-beta signaling in ErbB2/Neu-induced tumors from transgenic mice Oncogene 24 5173 5190
30. A Mackay C Jones T Dexter 2003 cDNA microarray analysis of genes associated with ERBB2 (HER2/neu) overexpression in human mammary luminal epithelial cells Oncogene 22 2680 2688
31. S Detre S Riddler J Salter 2003 Comparison of the selective estrogen receptor modulator arzoxifene (LY353381) with tamoxifen on tumor growth and biomarker expression in an MCF-7 human breast cancer xenograft model Cancer Res 63 6516 6522
32. T Itoh K Karlsberg I Kijima 2005 Letrozole-, anastrozole-, and tamoxifen-responsive genes in MCF-7aro cells: a microarray approach Mol Cancer Res 3 203 218
33. VN Kristensen T Sorlie J Geisler 2005 Effects of anastrozole on the intratumoral gene expression in locally advanced breast cancer J Steroid Biochem Mol Biol 95 105 111
34. C Scafoglio C Ambrosino L Cicatiello 2006 Comparative gene expression profiling reveals partially overlapping but distinct genomic actions of different antiestrogens in human breast cancer cells J Cell Biochem 98 1163 1184
35. T Sorlie CM Perou R Tibshirani 2001 Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications Proc Natl Acad Sci USA 98 10869 10874
36. A Mackay A Urruticoechea JM Dixon 2007 Molecular response to aromatase inhibitor treatment in primary breast cancer Breast Cancer Res 9 R37
37. S Chen S Masri X Wang 2006 What do we know about the mechanisms of aromatase inhibitor resistance? J Steroid Biochem Mol Biol 102 232 240
38. M Becker A Sommer JR Kratzschmar 2005 Distinct gene expression patterns in a tamoxifen-sensitive human mammary carcinoma xenograft and its tamoxifen-resistant subline MaCa 3366/TAM Mol Cancer Ther 4 151 168
39. D Meijer T van Agthoven PT Bosma 2006 Functional screen for genes responsible for tamoxifen resistance in human breast cancer cells Mol Cancer Res 4 379 386
40. T Shioda J Chesnes KR Coser 2006 Importance of dosage standardization for interpreting transcriptomal signature profiles: evidence from studies of xenoestrogens Proc Natl Acad Sci USA 103 12033 12038
41. ML Whitfield LK George GD Grant 2006 Common markers of proliferation Nat Rev Cancer 6 99 106
42. MP Jansen JA Foekens IL van Staveren 2005 Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling J Clin Oncol 23 732 740
43. S Tozlu-Kara V Roux C Andrieu 2007 Oligonucleotide microarray analysis of estrogen receptor alpha-positive postmenopausal breast carcinomas: identification of HRPAP20 and TIMELESS as outstanding candidate markers to predict the response to tamoxifen J Mol Endocrinol 39 305 318
44. M Brys M Wojcik H Romanowicz-Makowska 2002 Androgen receptor status in female breast cancer: RT-PCR and Western blot studies J Cancer Res Clin Oncol 128 85 90
45. F Moinfar M Okcu O Tsybrovskyy 2003 Androgen receptors frequently are expressed in breast carcinomas: potential relevance to new therapeutic strategies Cancer 98 703 711
46. A Ayyanan G Civenni L Ciarloni 2006 Increased Wnt signaling triggers oncogenic conversion of human breast epithelial cells by a Notch-dependent mechanism Proc Natl Acad Sci USA 103 3799 3804
47. LC Hodges JD Cook EK Lobenhofer 2003 Tamoxifen functions as a molecular agonist inducing cell cycle-associated genes in breast cancer cells Mol Cancer Res 1 300 311
48. A Bedirian C Baldwin J Abe 2004 Pleckstrin homology and phosphotyrosine-binding domain-dependent membrane association and tyrosine phosphorylation of Dok-4, an inhibitory adapter molecule expressed in epithelial cells J Biol Chem 279 19335 19349
49. M Franco O Furstoss V Simon 2006 The adaptor protein Tom1L1 is a negative regulator of Src mitogenic signaling induced by growth factors Mol Cell Biol 26 1932 1947
50. TP Dooley R Haldeman-Cahill J Joiner 2000 Expression profiling of human sulfotransferase and sulfatase gene superfamilies in epithelial tissues and cultured cells Biochem Biophys Res Commun 277 236 245
51. B Tang M Vu T Booker 2003 TGF-beta switches from tumor suppressor to prometastatic factor in a model of breast cancer progression J Clin Invest 112 1116 1124
52. DJ Slamon B Leyland-Jones S Shak 2001 Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 783 792
53. N Todorovic-Rakovic 2005 TGF-beta 1 could be a missing link in the interplay between ER and HER-2 in breast cancer Med Hypotheses 65 546 551
54. DS Oh MA Troester J Usary 2006 Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers J Clin Oncol 24 1656 1664